Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq, and 15 mEq. According to IMS data, the US market for Potassium Citrate is approximately $110 million.
The company will be the second generic player to commercialize the product. The product, which is the first approval for an Extended Release tablet for the company, will be launched immediately.
Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.
